Appeal

ANH: UK Court gives MHRA 'firm rap across the knuckles'

UK court ruling spells trouble for glucosamine

20-Jun-2016 By Shane STARLING

The UK Court of Appeal has ruled that glucosamine products above 1500 mg can be sold as food supplements, but has urged the UK medicines agency to look at the matter.

GMA et al file appeal vs Vermont GMO ruling, but they are running out of time, say attorneys

07-May-2015 By Elaine Watson

As widely predicted, the Grocery Manufacturers Association (GMA) is appealing a federal court ruling denying its bid to halt implementation of Vermont’s GMO labeling law (Act 120) until a lawsuit over the Act is resolved.

Attorney: This case could end up in the Supreme Court

What does the ruling in Vermont mean for GMO labeling?

30-Apr-2015 By Elaine Watson

While opponents of Vermont’s GMO labeling Act 120 suffered a major setback this week after a federal judge rejected many of their arguments, some attorneys predict the case could ultimately end up in the Supreme Court to settle a long-running debate over...

Court reins in FTC on two trials standard but otherwise supports agency in decision on POM’s claims

16-Feb-2015 By Hank Schultz

The Federal Trade Commission has received confirmation of its basic positions in its struggle with POM Wonderful over the substantiation on the claims the company has made for its juice and supplement products. But the appeals court ruling offers a shred...

FTC vs POM: Federal appeals court upholds FTC findings, but 2 RCTs are ‘too onerous’

30-Jan-2015 By Stephen Daniells

A federal appeals court in the District of Columbia has upheld an earlier court ruling in favor of the FTC versus POM Wonderful and claims it made in its advertising. On the flip side, the court also stated that requiring two valid clinical trials to...

USPTO rejects one of Neptune's krill patents; appeal forthcoming

16-May-2013 By Hank Schultz

In the latest development in the nutraceutical world’s equivalent of the Wars of the Roses, the United States Patent and Trademark Office has ruled on a reexamination of a Neptune Bioressources and Technologies patent and has rejected all of its 148 claims.